MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
FLDM - Fluidigm Corp
$5.22
-0.13(-2.43%)8:00:00 PM 10/21/2021
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments, consumables, and services to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. Fluidigm Corporation sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
Peers

Stock news

    10/20/2021FLDM
    Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results

    SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on Novem

    10/18/2021FLDM
    Fluidigm 2021 IMC Summit Focuses on ‘Uncovering Spatial Biology’

    Latest Imaging Mass Cytometry Discoveries in Infectious Disease, Immuno-Oncology and the Tumor Microenvironment from Expert Users of the TechnologySOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the agenda for its IMC™ Summit: Uncovering Spatial Biology. The October 21 virtual event highlights research insights attained

    10/12/2021FLDM
    Fluidigm Announces New Co-Marketing Program under Collaboration Agreement with Visiopharm, Offering AI-Based Image Analysis Software

    Native Reading of Hyperion Imaging System Data Files on the Visiopharm Platform to Streamline Data Analysis for ResearchersSOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a new co-marketing program to offer Visiopharm® image analysis software for faster and more streamlined analysis of data acquired through Imaging Mass

    09/28/2021FLDM
    Fluidigm Announces Collaboration Agreement with Karolinska Institutet to Accelerate Customer Adoption of New CyTOF XT

    Department of Women’s and Children’s Health to Work with Fluidigm on CyTOF Research Applications, Product DevelopmentSOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a collaboration agreement with the Karolinska Institutet for research applications and product development utilizing CyTOF® XT, the fourth-generation platfo

    09/2/2021FLDM
    Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the following investor event: Cantor Virtual Global Healthcare C

    08/31/2021FLDM
    CyTOF and Maxpar Direct Technologies Utilized in Study Characterizing Immune and Inflammatory Responses in Pregnant Women Infected with SARS-CoV-2

    Findings in Nature Communications Provide Insights That May Help Guide Patient Care Research Study Conducted in Collaboration with Fluidigm’s Therapeutic Insights Services SOUTH SAN FRANCISCO, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the publication of new data further validating the potential of its mass cytometry technologies, inclu

    08/10/2021FLDM
    Investors in Fluidigm (NASDAQ:FLDM) have unfortunately lost 25% over the last five years

    While not a mind-blowing move, it is good to see that the Fluidigm Corporation ( NASDAQ:FLDM ) share price has gained...

    08/9/2021FLDM
    Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit

    SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that company management will participate in the following investor event: UBS Genomics 2.0 and MedTech Innovations SummitWednesday, August 11, 2021Laguna Beach, CaliforniaPanel presentation at 8:00 p.m. ET, 5:00 p.m. PT The panel presentation includes a Fluidigm Imaging Mas